Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2024-201137

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Yuqin Song, Ningjing Lin, Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinna Ma, Miao Hu, Yanping Zhang, Jia Li, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2024-200544

Published: 2024

Journal Articles

Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia

Xiaowu Dong, Yu Guo, Jingyu Zhang, Zheyuan Shen, Shuang Wu, Shuangshuang Geng, Xinna Ma, Miao Hu, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 156.

https://doi.org/10.1182/blood-2024-201221

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin

Blood (2023) 142 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2023-185363

Published: 2023

Journal Articles

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xinglu Zhou

Blood (2023) 142 (Supplement 1): 3139.

https://doi.org/10.1182/blood-2023-185241

Published: 2023

Journal Articles

HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Yizhe Wu, Xingguo Liu, Xinxin Jin, Jiangfeng Xie, Haiyan Yang, Xinglu Zhou

Blood (2022) 140 (Supplement 1): 7818.

https://doi.org/10.1182/blood-2022-167261

Published: 2022

Journal Articles

Discovery and Preclinical Study of Novel BTK Degrader HZ-Q1060

Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinxin Jin, Haiyan Yang, Li Jia, Xinglu Zhou

Blood (2022) 140 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2022-167308

Published: 2022

Journal Articles

Discovery of HZ-L105, a Next Generation of Bcl-2 Inhibitor, Overcomes Bcl-2 Mutation and Exhibits Superior Antitumor Activity

Xingguo Liu, Yang Lou, Yizhe Wu, Mingbo Su, Anhui Gao, Jinglai Huang, Haiyan Yang, Li Zhong, Xinglu Zhou

Blood (2022) 140 (Supplement 1): 7798–7799.

https://doi.org/10.1182/blood-2022-166997

Published: 2022

Journal Articles

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Juying Wei, Wenjuan Yu, Hongyan Tong, Min Yang, Miao Hu, Xingguo Liu, Yizhe Wu, Xinglu Zhou, Jie Jin

Blood (2022) 140 (Supplement 1): 12065.

https://doi.org/10.1182/blood-2022-165195

Published: 2022

Journal Articles

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Zhuang Kang, Feng Chen, Yi Lin, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xingguo Liu, Xinglu Zhou, Wenbin Li

Blood (2022) 140 (Supplement 1): 12064.

https://doi.org/10.1182/blood-2022-166776

Published: 2022

NARROW

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies

Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Discovery and Preclinical Study of Novel BTK Degrader HZ-Q1060

Discovery of HZ-L105, a Next Generation of Bcl-2 Inhibitor, Overcomes Bcl-2 Mutation and Exhibits Superior Antitumor Activity

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only